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Abstract
Aim: This study tests the hypothesis that salivary extracellular RNA (exRNA) bio-
markers can be developed for gingivitis detection and monitoring disease 
regression.
Materials and Methods: Salivary exRNA biomarker candidates were developed from a 
total of 100 gingivitis and non- gingivitis individuals using Affymetrix’s expression mi-
croarrays. The top 10 differentially expressed exRNAs were tested in a clinical cohort 
to determine whether the discovered salivary exRNA markers for gingivitis were as-
sociated with clinical gingivitis and disease regression. For this purpose, unstimulated 
saliva was collected from 30 randomly selected gingivitis subjects, the gingival and 
plaque indexes scores were taken at baseline, 3 and 6 weeks and salivary exRNAs 
were assayed by means of reverse transcription quantitative polymerase chain 
reaction.
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1  | INTRODUC TION
Periodontal diseases are the most common inflammatory diseases in 
humankind (Kassebaum et al., 2017). Gingivitis, the reversible form 
of the disease, is induced by the accumulation of bacterial biofilm 
that can be treated with professional biofilm removal and improve-
ment in oral hygiene (Kim, Kim, & Camargo, 2013). If left untreated, 
gingivitis may progress to an irreversible form—periodontitis that in-
volves bone and attachment loss. Periodontitis can advance to the 
point that it induces tooth mobility and tooth loss (Kim et al., 2013). 
It may also adversely influence systemic health via cardiovascular 
diseases (Kim et al., 2013), ischemic stroke (Grau et al., 2004) or can-
cers (Binder Gallimidi et al., 2015; Mitsuhashi et al., 2015; Rajesh, 
Thomas, Hegde, & Kumar, 2013). The common risk factors for peri-
odontitis could be divided into inherited (e.g. genetic variants), and 
those that are acquired (e.g. socioeconomic factors, poor oral hy-
giene, cigarette smoking and diabetes) (Chapple et al., 2017).
The quest to develop salivary biomarkers for periodontal dis-
eases has been elusive (Giannobile et al., 2009). Despite the scien-
tific acceptance of salivary biomarkers for the detection of gingivitis 
(Henskens, Van Der Velden, Veerman, & Nieuw Amerongen, 1993; 
Kinney et al., 2011; Lee et al., 2012; Morelli et al., 2014; Shaila, Pai, 
& Shetty, 2013), the absence of definitively validated biomarkers 
did not allow for such technology to receive regulatory approval 
and translating this diagnostic test to move into clinical practice. 
Presently, the gold standard for early detection and diagnosis for gin-
givitis includes a comprehensive periodontal exam along with clinical 
examination (i.e. redness, swelling or gingival bleeding) performed 
during dental examinations. Unfortunately, the absence of pain in 
gingivitis often renders individuals unaware of their pathological gin-
gival condition, particularly if they do not have to visit the dentist 
regularly (Kim et al., 2013). While very helpful, clinical parameters do 
not provide full information about the current status of the disease 
activity, patient- specific variations, do not predict non- responders 
for treatment therapy and those who are “at risk” for disease pro-
gression (Ebersole, Nagarajan, Akers, & Miller, 2015). Thus, it is de-
sirable to develop objective and scientifically credible biomarkers for 
early detection and monitoring of periodontal diseases, especially 
that many of the affected cases are left undiagnosed and untreated 
(Albandar & Kingman, 1999; Tomar & Asma, 2000).
The applications of such biomarkers could be multiple. Firstly, 
they might be used by community at large as self- administered 
point- of- care (POC) tests to screen for periodontal diseases, 
thus making people aware of the pathology in their oral cavities 
and to encourage them to search for a dental care. The chairside 
POC devices will require minimal clinical training and resources, 
lead to simpler, more cost- effective and less intensive treatment 
(Giannobile, 2012). Due to close proximity of saliva to periodon-
tal tissues and its easy collection, saliva constitutes a valuable di-
agnostic source, specifically as its collection is easy, repeatable 
and can be performed by auxiliary personnel. In addition, the 
salivary biomarkers present an attractive tool for quantitative 
Results: Eight salivary exRNA biomarkers developed for gingivitis were statistically 
significantly changed over time, consistent with disease regression. A panel of four 
salivary exRNAs [SPRR1A, lnc- TET3- 2:1, FAM25A, CRCT1] can detect gingivitis with 
a clinical performance of 0.91 area under the curve, with 71% sensitivity and 100% 
specificity.
Conclusions: The clinical values of the developed salivary exRNA biomarkers are as-
sociated with gingivitis regression. They offer strong potential to be advanced for 
definitive validation and clinical laboratory development test.
K E Y W O R D S
biomarkers, exRNA, gingivitis, monitoring, saliva
Clinical Relevance
Scientific rationale for the study: Presently, the gold 
standard for diagnosis of gingivitis includes mainly clini-
cal examination. As a companion diagnostics, scientifi-
cally based evaluation of gingivitis would be very 
beneficial as it is the most prevalent inflammatory dis-
ease in humans.
Principal findings: Principles of prospective study design 
(PRoBE) and rigorous clinical classification of gingivitis led 
to the development and validation of salivary exRNA bio-
markers for gingivitis detection that are associated with 
disease regression. Discriminatory salivary exRNA bio-
markers were developed for gingivitis detection. Four sali-
vary exRNA panels can discriminate gingivitis from healthy 
periodontium with a performance of 0.91 AUC, with 71% 
sensitivity and 100% specificity.
Practical implications: Salivary exRNA markers can be ob-
jective molecular indicators of periodontal health for dis-
ease detection as well as gingivitis regression.
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and qualitative objective evaluation and monitoring of gingivitis 
for both scientists and dentists. The use of salivary- based POCs 
would also enable the underserved communities an improved 
access to oral health programmes as well as offers the ability to 
identify and monitor the patients at risk (Giannobile, 2012). Lastly, 
the dental, pharmaceutical and oral health care companies could 
use them for optimizing the pharmaceutical efficiency such as ad-
equate selection of target patients, optimal dose selection and to 
assess the performance of the current active compounds in the 
development of their new oral hygiene products such as tooth-
pastes, mouthwashes, etc.
This study addresses the unmet clinical need of assessing host 
factors as a companion diagnostics to detect gingivitis and monitor 
its treatment response.
2  | MATERIAL S AND METHODS
2.1 | Ethics statement
The sample collection was approved by the Institutional Review 
Board (IRB) at the University of California at Los Angeles (UCLA) for 
both the discovery phase (IRB#10- 000505) and the clinical stage 
(IRB#15- 001957) of the study. Each participant had to sign the in-
formed consent.
2.2 | Discovery phase
Based on the prospective- specimen- collection and retrospective- 
blinded- evaluation (PRoBE) study design (Pepe, Feng, Janes, 
Bossuyt, & Potter, 2008), saliva was collected prospectively from 
750 human subjects at the UCLA School of Dentistry. The inclusion 
and exclusion criteria are presented in Figure 1. Subjects were classi-
fied as healthy or gingivitis according to research and clinical criteria 
(Figure 1).
Prior to a clinical evaluation, unstimulated whole saliva was 
collected for every subject. Subjects were asked to avoid oral 
hygiene measures, eating, drinking or gum chewing at least 1 hr 
prior to saliva collection. All subjects rinsed with tap water (10 ml) 
for 30 s about 10 min prior to saliva collection and expectorated. 
Clinical samples were collected into sterile tubes, lasting 5–10 min 
per collection (at least 5 ml of saliva), and kept on ice through the 
entire process. All samples were processed, around 1 hr after 
collection. Samples were firstly centrifuged in a refrigerated cen-
trifuge at 2,400 × g for 15 min at 4°C, and the supernatant was 
processed immediately for the concurrent stabilization of proteins 
and RNA by the inclusion of a protease inhibitor cocktail (apro-
tinin, 3- phenylmethylsulfonyl fluoride [3- PMSF] [Sigma- Aldrich, 
St. Louis, MO, USA], sodium orthovanadate [Na3VO4] [Sigma-
Aldrich] RNase inhibitor (Invitrogen SUPERase·In RNase Inhibitor 
[Thermo Fisher Scientific, Austin, TX, USA]) based on our saliva 
standard operating procedure (Henson & Wong, 2010). These 
samples were aliquoted into smaller cryo- vials, labelled and fro-
zen at −80°C.
Afterwards, salivary exRNA was extracted using the RNeasy 
Micro Kit [Qiagen, Germantown, MD, USA] including DNase I diges-
tion. Samples with good purity QC (OD 260/280 ~1.8) were profiled 
using the GeneChip Human Transcriptome Affymetrix HTA 2.0 ex-
pression arrays [Thermo Fisher Scientific].
F IGURE  1 Study design: flow chart
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2.3 | Pilot clinical research study
The pilot study consisted of two stages: clinical and laboratory.
2.3.1 | Clinical stage
For analysis of saliva samples, 30 volunteers (aged 18–65 years), 
diagnosed with gingivitis, were included in this study. Figure 1 
presents the inclusion and exclusion criteria. The duration of this 
project was 7 weeks (including 1 week pretrial training “washout” 
period to check if there are any allergic reactions to toothpaste’s 
ingredients) and involved the same treatment protocol for gingi-
vitis such as brushing with toothpastes containing 1,000 p.p.m. 
sodium monofluorophosphate (Colgate- Palmolive Company, New 
York, NY, USA). Each volunteer was instructed to brush the whole 
mouth with a full ribbon of the toothpaste for 1 min twice daily. 
The subjects expectorated and rinsed with water. Subjects re-
turned for a clinic visit at baseline (B), 3 and 6 weeks to donate 
saliva samples prior to the clinical examination. The protocol for 
collection and processing of saliva was the same as described 
previously (discovery phase), but saliva was collected only in the 




The direct saliva transcriptome analysis For the validation phase, 
the direct saliva transcriptome analysis (DSTA) was performed that 
uses cell- free saliva supernatant instead of isolated messenger 
RNA (mRNA) for saliva transcriptomic detection (Lee et al., 2011). 
The validation was performed by means of reverse transcription 
quantitative polymerase chain reaction (RT- qPCR) in saliva taken 
from 30 gingivitis individuals in the clinical phase at B, 3 and 6 weeks. 
The qPCR associated with melting- curve analysis was conducted 
by the use of the LightCycler® 480 Real- Time PCR System [Roche 
Life Science, Indianapolis, IN, USA] with a fixed thermal- cycling 
programme.
2.3.2.2 | Statistical analysis
Kruskal–Wallis and chi- squared tests were performed to compare 
markers between healthy and gingivitis groups in the discovery 
phase of transcriptomic analysis. In the validation phase, the 
analysis of variance (ANOVA) was done at a significance level of 
p < 0.05. In addition, the logistic regression analysis in R was used 
to construct the final panel of biomarkers using the “best glm” 
function and the best Akaike Information Criterion. A paired t test 
along with the 95% confidence interval (CI) was used to compare 
the Löe- Silness Gingival Index (GI) (Loe, 1967) and the Quigley and 
Hein Plaque Index (PI) (Turesky Modification) (Quigley & Hein, 
1962; Turesky, Gilmore, & Glickman, 1970) scores over differ-
ent time periods. Furthermore, generalized estimating equation 
(GEE) models were added to show the overall trends in biomarker 
changes over time. Finally, inter- individual variability between two 
different clinical investigators was examined (the mean of each ex-
aminer’s patients clinical scores at each time point). The examiners 
in the study followed the same patients through the investigation. 
The statistical analyses were performed using R V3.1.2 (R Core 
Team, 2014) and SAS V9.4 (SAS Institute Inc., Cary, NC, USA), 
whereas the randomization was performed using the online sta-




In the discovery phase, the study group consisted of 100 subjects, 
including 50 gingivitis subjects (22 males and 28 females) aged 
26.4 ± 6.77 years, and 50 healthy individuals aged 27.1 ± 5.67 years 
(23 males and 27 females). The scores for the gingivitis group were 
7.2 ± 1.1% for Marginal Bleeding Index (MBI) (Loe, 1967; Muhlemann 
& Son, 1971) and 2.5 ± 0.7 mm for Probing Pocket Depth (PPD) 
(Ramfjord, 1959), while for the healthy group, the results were fol-
lowing: 2.4 ± 1.6% for MBI and 2.1 ± 0.8 mm for PPD. The partici-
pants were mainly of White origin (73%), but also Asian (17%), black 
or African American (10%).
The validation phase included 30 subjects (13 males and 17 
females), aged 28.2 ± 7.77 years. The participants were mainly 
of White origin (75%), but also Asian (20%) and black or African 
American (5%). The average GI scores were at Screening (Scr) 
1.75 ± 0.2, at B—1.814 ± 0.18, at 3 weeks—1.684 ± 0.26 and at 
6 weeks—1.46 ± 0.55, while the average PI scores were following: at 
Scr 2.293 ± 0.44, at B—2.307 ± 0.34, at 3 weeks—2.054 ± 0.33 and 
at 6 weeks—1.86 ± 0.36 (Supporting Information Table S1). Both GI 
and PI showed significantly decreased scores over time due to good 
oral hygiene regimens implemented by brushing with toothpastes 
(Figure 2). The GI scores improved for 60% and PI for 93.3% of sub-
jects over the period of 6 weeks.
Due to the long- term period of the study and large time difference 
between performing the discovery and the validation phases, there was 
a change in the current protocol for the enrolment of the patients into 
the study between the two stages. The MBI (Loe, 1967; Muhlemann 
& Son, 1971) applied in the discovery phase, was replaced later, in the 
validation phase, with the more commonly used indices such as GI 
(Loe, 1967) and PI (Quigley & Hein, 1962; Turesky et al., 1970) for the 
determination of the gingivitis status. The PPD (Ramfjord, 1959) was 
measured in both phases of the study. In the discovery phase, PPD 
was used to differentiate between healthy (non- periodontal disease) 
(PPD < 4 mm) and gingivitis (PPD < 4 mm) from periodontitis (≥5 mm) 
(apart from radiographic assessment). In the validation phase, only pa-
tients with diagnosed gingivitis were included. Study subjects could not 
have any PPD deeper than 5 mm (except for 3rd molars) to be enrolled 
in the research project.
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3.2 | Investigation of potential clinical 
evaluators bias
There were no significant inter- examiner differences between the clini-
cal evaluators, except for time point 6 weeks, which could potentially 
affect the GI and PI scores (Supporting Information Figure S1). This is 
despite the fact that all examiners were initially calibrated.
3.3 | Discovery of salivary exRNA biomarker 
candidates for gingivitis by HTA Microarray profiling
The 25 salivary exRNA biomarker candidates were identified from 
a discovery cohort of randomly selected 50 gingivitis and 50 age- /
gender- matched healthy controls (Table 1) (Figure 1). Of these, 10 
differentially expressed exRNA biomarker candidates between gin-
givitis and healthy groups were advanced for validation by means 
of RT- qPCR using an independent cohort of 30 gingivitis subjects in 
the pilot clinical research study. Those exRNA biomarker candidates 
were selected based on their known association with inflammation 
and periodontal diseases, low p value (p < 0.05) and high absolute 
fold change in their expression levels between gingivitis and healthy 
groups.
3.4 | Validation of 10 salivary exRNA biomarker 
candidates for gingivitis by RT- qPCR
Eight out of 10 validated exRNA targets were concordant with 
the HTA 2.0 microarray data (Table 2), including four decreased 
exRNAs [SPRR1A (m1), LGALS3 (m4), FAM25A (m7), CRCT1 
(m10)] and four increased exRNAs [lnc- TET3- 2:1 (m2), RP5- 
965F6.2 (m3), GALNT10 (m5), SOX4 (m6)] over time (B–3 weeks, 
3 weeks–6 weeks, B–6 weeks) (GEE p values < 0.001) (Supporting 
Information Figure S2, Supporting Information Table S1). Figure 3 
presents a plot with fold changes and 95% CIs for each marker at B, 
3 and 6 weeks. The increase in their alteration levels compared to 
the initial data might be a result of the inter- individual variability in 
exRNA patterns.
3.5 | Logistic regression analysis
The potential clinical discriminatory power of the developed sali-
vary exRNA for gingivitis detection was evaluated. Logistic regres-
sion analysis of eight validated exRNAs revealed that four exRNA 
marker model [SPRR1A (m1), lnc- TET3- 2:1 (m2), FAM25A (m7), 
CRCT1 (m10)] could potentially provide a discriminatory perfor-
mance of 0.91 area under the curve with 71% sensitivity and 100% 
specificity (Figure 4).
4  | DISCUSSION
Saliva is a complex body fluid that is composed of unique molecular 
constituents (proteins, DNA, RNA, etc.) that can be discriminatory 
for oral and systemic disease screening, detection and monitoring 
(Kaczor- Urbanowicz et al., 2017). The development of non- invasive 
salivary test based on molecular biomarkers could have impactful 
clinical applications, providing accurate and real- time monitoring of 
periodontal disease activity for the general public at home or at the 
dental clinic. Although proteins are the essential effectors of cellular 
function, the eukaryotic complexity and phenotypic variation lies in 
a control of trans- acting RNAs—noncoding RNAs (ncRNAs) (Wong, 
2015). NcRNAs regulate diverse biological functions, thus being 
very attractive for the development of new target therapies and dis-
covery of new diagnostic biomarkers in human body fluids, including 
saliva (Ainsztein et al., 2015). The human salivary transcriptome was 
firstly described in 2004 (Li, Zhou, St John, & Wong, 2004), followed 
by the intense investigations in the following years (Nussbaumer, 
Gharehbaghi- Schnell, & Korschineck, 2006). The revealed complex 
exRNA composition of saliva encompasses mostly mRNAs, but 
also ncRNAs such as long noncoding RNAs (lncRNAs), microRNAs 
(miRNAs), small nucleolar RNAs (snoRNAs), piwi- interacting RNAs 
(piRNAs), etc. (Wong, 2015). Among all ncRNAs, small ncRNAs are 
the most exploited exRNAs in saliva, particularly miRNAs that play 
an important role in regulating various biological processes (Nelson, 
Kiriakidou, Sharma, Maniataki, & Mourelatos, 2003), while the cur-
rent knowledge of lncRNAs is still largely uninvestigated (Kung, 
Colognori, & Lee, 2013).
The basis of biomarker research success in periodontology is to 
develop a diagnostic method that will have a potential to favourably 
affect clinical decision- making, patient outcomes and health care 
providers (Ghallab, 2017). Periodontal disease is time- consuming 
and expensive to treat, thus prevention and early detection consti-
tutes significant health care benefit (Ghallab, 2017). Thus, it would 
be desirable to develop biomarkers for early detection and monitor-
ing of periodontal disease and its treatment response (Giannobile 
et al., 2009).
F IGURE  2 Comparison of the Gingival 
Index and the Plaque Index scores over 
time
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In the present study, the objective was to validate exRNA bio-
markers for gingivitis, and to evaluate their potential to monitor 
disease regression. Eight salivary exRNAs showed significant pos-
itive correlation of their expression levels with improving clinical 
measures (GI, PI) due to the introduced treatment (brushing teeth), 
thus making them potentially useful in monitoring the current ac-
tivity of disease and its treatment response. The identified exRNAs 
are mostly involved in inflammatory response, antimicrobial activity, 
innate immune response, apoptosis, neutrophil, eosinophil & macro-
phage chemotaxis, and bone homeostasis, that is consistent with the 
current literature as periodontal diseases are mostly inflammatory 
in origin and involved in immune pathways (Ghallab, 2017) (Table 3). 
Interestingly, only very few of them had been previously reported in 
different biofluids, but none of them have been identified in human 
saliva. Specifically, lncRNAs have aroused a lot of widespread inter-
est in recent years as potentially associated in inducing particular 
diseases or developmental processes, but knowledge of the par-
ticular pathogenetic mechanisms by which they act is still limited. 
Therefore, it is not surprising that in the current literature, not much 
information can be found about the developed in this study—three 
lncRNA biomarkers of gingivitis (SPRR1A, lnc- TET3- 2 and RP5- 
965F6.2). It is known only that SPRR1A (m1) is a regeneration- 
associated gene (Starkey et al., 2009), whereas lnc- TET3- 2:1 (m2) 
TABLE  2 Concordance of the 10 salivary exRNA biomarker changes with initial microarray data
No. Gene symbol Gene accession
Association with disease
Microarray fold change PCR slope
Direction p- Value Direction p- Value
m1 SPRR1A NONHSAT006501.2 − 0.044 − <0.001
m2 lnc- TET3- 2:1 NONHSAT071649 + <0.001 + <0.001
m3 RP5- 965F6.2 NONHSAT005224 + <0.001 + <0.001
m4 LGALS3 NR_003225 − 0.025 − <0.001
m5 GALNT10 NM_198321 + <0.001 + <0.001
m6 SOX4 AJ420500 + 0.020 + <0.001
m7 FAM25A NM_001146157 − 0.023 − 0.003
m8 AL832615 XM_294900.1 − <0.001 NS 0.867
m9 SLPI NM_003064 − 0.049 NS 0.088
m10 CRCT1 NM_019060 − 0.046 − <0.001
Notes. Values reported as direction of effect ± and p value for statistical significance.
NS: nonsignificant.
F IGURE  3 Validation of HTA 2.0 Affymetrix array profiling 
results by RT- qPCR. A plot presenting the fold changes and 95% 
confidence interval (CI) for each of 10 salivary exRNA biomarkers 
on the log base 2 scale for the following periods: baseline–6 weeks, 
3 week–6 weeks and baseline–3 weeks
F IGURE  4 Performance of salivary exRNA biomarkers to 
classify gingivitis from healthy subjects with no periodontal disease 
(baseline–6 weeks) [4 exRNAs: SPRR1A (m1), lnc- TET3- 2:1 (m2), 
FAM25A (m7), CRCT1 (m10)] (0.91 AUC, 71% sensitivity, 100% 
specificity)
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acts as an epigenetic mediator (Langemeijer, Aslanyan, & Jansen, 
2009) (Table 3).
In addition, our study also revealed five mRNA RNAs (LGALS3, 
GALNT10, SOX4, FAM25A and CRCT1) that are an emerging 
and flourishing field for non- invasive diagnostic applications. 
The identification of saliva- derived mRNA in normal and cancer 
patients (Hu et al., 2008; Li et al., 2004) and other forensic appli-
cations (Juusola & Ballantyne, 2005) have opened up a new ave-
nue for further clinical usage. According to the literature, LGALS3 
(m4) can be informative on the inflammatory and bacterial na-
ture of gingivitis due to their connectivity to the disease- related 
features such as its involvement in specific cellular (apoptosis, 
No. Gene symbol Gene accession Function/biological role
m1 SPRR1A NONHSAT006501.2 Epidermatitis development, keratinocyte 
differentiation and keratinization (Gibbs 
et al., 1993; Stemmler et al., 2009)
Assessment of the regenerative potential of 
injured neurons (Starkey et al., 2009)
m2 lnc- TET3- 2:1 NONHSAT071649 A member of the ten- eleven translocation 
(TET) gene family, that plays a role in the 
DNA methylation process (Langemeijer 
et al., 2009)
m3 RP5- 965F6.2 NONHSAT005224 Has not been reported yet in the 
publications
m4 LGALS3 NR_003225 A member of the galectin family of 
carbohydrate- binding proteins that play a 
role in apoptosis, innate immunity, 
neutrophil, eosinophil & macrophage 
chemotaxis and negative regulation of 
endocytosis
Antimicrobial activity against bacteria and 
fungi (http://www.genecards.org) (Raz 
et al., 1991)
Association with increased risk for 
rheumatoid arthritis (Atabaki, Hashemi, 
Daneshvar, & Alijani, 2017)
m5 GALNT10 
AJ156166
NM_198321 Homo sapiens putative tumour suppressor 
mRNA (https://www.ncbi.nlm.nih.gov/
nuccore) (Boultwood et al., 2000)
m6 SOX4 AJ420500 Apoptosis pathway leading to cell death as 
well as to tumorigenesis
Mediation of downstream effects of 
parathyroid hormone (PTH) and PTH- 
related protein (PTHrP) in bone develop-
ment (http://www.genecards.org)
Obesity and type 2 diabetes (Ragvin et al., 
2010)
Airway inflammation (Kuwahara et al., 
2012)
m7 FAM25A NM_001146157 Inflammation and infectious disease, 
decrease in immune response (Deloukas 
et al., 2004; Mauritz et al., 2010; Wang 
et al., 2014)
m10 CRCT1 NM_019060 Linkage to oesophageal cancer (Wu, Song, 
Pang, & Chen, 2016) and oropharyngeal 
squamous cell carcinomas (Masterson 
et al., 2015)
Early Alzheimer’s disease- related stages 
(Parra- Damas et al., 2014)
Promotion of tumour cell apoptosis and 
upregulation of the expression of 
apoptosis- related proteins (Wu et al., 
2016)
TABLE  3 Description of functions and 
biological roles of validated exRNAs for 
gingivitis
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neutrophil, eosinophil and macrophage chemotaxis, etc.) and bi-
ological functions (antimicrobial activity, etc.) (Raz et al., 1991) 
(Table 3). As expected, in gingivitis due to gum inflammation, de-
creased levels of LGALS3 can be observed, that is concordant 
with our findings. In turn, alterations in SOX4 (m6) expression, 
induced by transforming growth factor beta, regulate T- helper 
type 2 (TH2) cell- driven airway inflammation (Kuwahara et al., 
2012), whereas downregulation of FAM25A (m7) (observed also 
in our study) indicates increased risk for inflammation and infec-
tious diseases (Deloukas et al., 2004; Mauritz et al., 2010; Wang, 
Kou, Wang, Cederbaum, & Wang, 2014). Lastly, CRCT1 (m10) is 
reported to be associated with early stages of Alzheimer’s dis-
ease, in which transcriptome changes affecting cell signalling, 
inflammation and neurotransmission pathways take place before 
the neuropathology in brains occur. In addition, the involvement 
of CRCT1 in protection against infection and inflammation is 
currently being explored (Parra- Damas et al., 2014) (Table 3). 
Thus, the potential role of the eight validated in this study exR-
NAs in pathogenetic mechanisms of periodontal diseases can be 
explained through their biological roles and potential functions 
(Table 3).
The major advantage of the study was the use of saliva, col-
lected in a prospective way, as a potential non- invasive diagnos-
tic source for detection and monitoring of gingivitis. Secondly, our 
study was focused on long RNAs as potential salivary biomarkers 
of periodontal diseases, including novel finding of lncRNAs, while 
the current literature reports mostly on short RNAs (microRNAs) 
with rather unsatisfactory performance (Kagiya, 2016; Ogata et al., 
2014; Schmalz et al., 2016). Lastly, the use of DSTA method, that 
omits the step of RNA extraction, seems to be much more conve-
nient and practical way of performing the experimental stage, as 
RNA isolation from saliva is not easy to perform and requires dili-
gent protocol.
The main limitation of the study was the inter- individual dif-
ferences in scoring of PI and GI, which suggest that a better sys-
tem of clinical evaluation for gingivitis is largely needed, such as 
changes in expression levels of exRNA biomarkers, that can be 
used as companion diagnostic tool for periodontal and clinical 
examinations.
In addition, the same inclusion and exclusion criteria for clinical 
evaluation of the periodontal status (the same periodontal indices 
for both discovery and validation phases) are recommended to be 
used for the enrolment of the subjects into the project. Lastly, a 
comprehensive study of the variety of exRNAs and further increased 
sampling is needed to establish the sensitivity and specificity of the 
final panel of salivary exRNA biomarkers for gingivitis.
In fact, different groups have studied the exRNA composi-
tion of saliva for detection of periodontal diseases. Inflammatory 
mRNA markers for interferon gamma (IFNγ) and tumour necrosis 
factor alpha can be detected in whole saliva to monitor the status 
of periodontal disease in type II diabetes patients (Gomes et al., 
2006). mRNA expression of human beta defensin- 1 and - 2 in the 
gingival tissue is associated with gingivitis, aggressive and chronic 
periodontitis (Vardar- Sengul et al., 2007). Also, the expression 
levels of Toll- like receptors (TLR)TLR2, - 4, - 7, - 9, interferon- 
alpha1 (IFN- α1) (Kajita et al., 2007) and MYD88 mRNAs were sig-
nificantly lower in gingivitis than in severe periodontitis lesions 
(Ghaderi et al., 2014). In addition, four miRNAs (hsa- miR- 451, 
hsa- miR- 223, hsa- miR- 486- 5p and hsa- miR- 3917) were signifi-
cantly overexpressed, and seven (hsa- miR- 1246, hsa- miR- 1260, 
hsa- miR- 141, hsa- miR- 1260b, hsa- miR- 203, hsa- miR- 210 and hsa- 
miR- 205) were underexpressed by > twofold in a diseased com-
pared to healthy gingiva (Stoecklin- Wasmer et al., 2012). In turn, 
Bochenek et al. (2013) report about downregulation of lncRNA 
ANRIL associated with atherosclerosis, periodontitis and several 
forms of cancer.
Several studies in the last decades have focused on finding 
a precise method for the diagnosis of periodontal disease in its 
early stages, such as gingivitis, as well as to monitor its treatment 
and progression into periodontitis. Interleukin 1 beta (IL- 1β) can 
be considered as an indicator of periodontal disease progression 
(Nazar Majeed, Philip, Alabsi, Pushparajan, & Swaminathan, 2016), 
whereas matrix metalloproteinase- 8 (MMP- 8) may indicate re-
sponse to therapy (Sexton et al., 2011). Additionally, macrophage 
inflammatory protein- 1α (MIP- 1α) appeared to increase prediction 
of periodontitis progression (Fine et al., 2009) and to decrease 
its levels following periodontal therapy (Al- Sabbagh et al., 2012; 
Sexton et al., 2011).
Recent advances in transcriptomic high- throughput technol-
ogies are shedding a new light on salivary biomarker discovery, 
which can advance salivary diagnosis of periodontal diseases to a 
higher level. Salivary biomarkers for periodontal diseases need to 
have the intended clinical context to obtain approval from the Food 
and Drug Administration. The PRoBE design, applied in our study, 
greatly facilitates the future translation of the biomarkers into the 
everyday dental practice (Kim et al., 2013). Our results indicate that 
salivary exRNAs represent a promising source of biomarkers for gin-
givitis as well as monitoring disease regression. Although challenges 
emerge, using saliva seems to have a bright future in early detection 
of periodontal diseases and monitoring of periodontal treatment 
outcomes.
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